Arovella Therapeutics (ALA) Investor Presentation summary

Investment highlights and strategic positioning

• Developing off-the-shelf iNKT cell therapies to address blood cancers and solid tumors, with a proprietary clinic-ready manufacturing process and a focus on strategic acquisitions to strengthen the platform.

• Leadership team has proven experience in drug development, particularly in cell therapies, and is focused on addressing key unmet needs in the cell therapy sector.

• Lead product ALA-101, targeting CD19-positive blood cancers, is advancing toward phase 1 clinical trials expected to commence in early 2026.

Financial overview

• Market capitalization stands at $113.62 million with 1,183.9 million shares on issue and a cash balance of $20.9 million as of June 30, 2025.

• Major shareholders include Merchant Funds Management and Netwealth Investments, each holding over 2% of shares.

• Share price ranged from $0.068 to $0.210 over the past 52 weeks.

Industry landscape and recent transactions

• Recent cell therapy deals highlight significant investments, with acquisitions and collaborations in the sector reaching up to $2.1 billion in total deal value.

• iNKT cell therapies are gaining attention, with notable deals such as Appia Bio's preclinical iNKT cell platform valued at $875 million.